Management of impulse control disorders in Parkinson's disease: Controversies and future approaches

Impulse control disorders in Parkinson's disease are a group of impulsive behaviors most often associated with dopaminergic treatment. Presently, there is a lack of high quality evidence available to guide their management. This manuscript reviews current management strategies, before concentrating on the concept of dopamine agonist withdrawal syndrome and its implications for the management of impulse control disorders. Further, we focus on controversies, including the role of more recently available anti‐parkinsonian drugs, and potential future approaches involving routes of drug delivery, nonpharmacological treatments (such as cognitive behavioral therapy and deep brain stimulation), and other as yet experimental strategies. © 2015 International Parkinson and Movement Disorder Society

[1]  R. Brown,et al.  Behavioural disorders, Parkinson's disease, and subthalamic stimulation , 2002, Journal of neurology, neurosurgery, and psychiatry.

[2]  J. Lisman,et al.  The Hippocampal-VTA Loop: Controlling the Entry of Information into Long-Term Memory , 2005, Neuron.

[3]  J. Brotchie,et al.  The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[4]  A. Berney,et al.  Rapid Resolution of Dopamine Dysregulation Syndrome (DDS) After Subthalamic DBS for Parkinson Disease (PD): A Case Report , 2008, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[5]  Zhentao Zhang,et al.  Impulsive and Compulsive Behaviors in Parkinson’s Disease , 2014, Front. Aging Neurosci..

[6]  K. Chaudhuri,et al.  European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD , 2012 .

[7]  Martin N. Rossor,et al.  Advanced online publication. , 2005, Nature structural biology.

[8]  Catechol‐O‐Methyltransferase Genotype Modulates Opioid Release in Decision Circuitry , 2013, Clinical and translational science.

[9]  H. Bowden-Jones,et al.  Pathological gambling and the treatment of psychosis with aripiprazole: case reports , 2011, British Journal of Psychiatry.

[10]  Paul Krack,et al.  Mirthful laughter induced by subthalamic nucleus stimulation , 2001, Movement disorders : official journal of the Movement Disorder Society.

[11]  Ji Hyun Ko,et al.  Dopamine‐agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions , 2014, Human brain mapping.

[12]  P. Calabresi,et al.  New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease , 2013, The Lancet Neurology.

[13]  A. Lang,et al.  Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine , 2012, Movement disorders : official journal of the Movement Disorder Society.

[14]  M. Okun,et al.  Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? , 2013, Movement disorders : official journal of the Movement Disorder Society.

[15]  T. Banaschewski,et al.  Genetics of preparation and response control in ADHD: the role of DRD4 and DAT1. , 2014, Journal of child psychology and psychiatry, and allied disciplines.

[16]  A. Rotondo,et al.  Clozapine for medication‐related pathological gambling in Parkinson disease , 2010, Movement Disorders.

[17]  Keith Wheatley,et al.  Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial , 2010, The Lancet Neurology.

[18]  Mark Stacy,et al.  Clinical spectrum of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[19]  D. Bowers,et al.  Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation. , 2011, The Journal of neuropsychiatry and clinical neurosciences.

[20]  A. Cunnington,et al.  Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. , 2012, Parkinsonism & related disorders.

[21]  L. Tremblay,et al.  Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.

[22]  R. Roth,et al.  Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys , 1999, Psychopharmacology.

[23]  J. Kulisevsky,et al.  Mania following deep brain stimulation for Parkinson's disease. , 2002, Neurology.

[24]  D. Stein,et al.  Pathological gambling behaviour: Emergence secondary to treatment of Parkinson's disease with dopaminergic agents , 2000, Depression and anxiety.

[25]  A. Grace,et al.  Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[26]  D. Consoli,et al.  Opioid Antagonist Naltrexone for the Treatment of Pathological Gambling in Parkinson Disease , 2012, Clinical neuropharmacology.

[27]  P. Christos,et al.  Prospective cohort study of impulse control disorders in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[28]  J. Brotchie,et al.  Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.

[29]  Ji Hyun Ko,et al.  Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study , 2012, Neurobiology of Disease.

[30]  K. Lyons,et al.  Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects , 2010, Clinical neuropharmacology.

[31]  A. Akyol,et al.  Quetiapine in a case with Parkinson disease and pathological gambling. , 2007, Journal of clinical psychopharmacology.

[32]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[33]  M. Mata,et al.  Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  C. Baumann,et al.  Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. , 2012, Parkinsonism & related disorders.

[35]  M. Jahanshahi,et al.  Parkinson's Disease, the Subthalamic Nucleus, Inhibition, and Impulsivity , 2015, Movement disorders : official journal of the Movement Disorder Society.

[36]  E. Granieri,et al.  Explosive-aggressive behavior related to bilateral subthalamic stimulation. , 2004, Parkinsonism & related disorders.

[37]  H. Berendse,et al.  Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin? , 2014, Neuroscience & Biobehavioral Reviews.

[38]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Matsumoto,et al.  Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.

[40]  F. Limosin,et al.  Manic episode with psychotic symptoms in a patient with Parkinson's disease treated by subthalamic nucleus stimulation: Improvement on switching the target , 2008, Journal of the Neurological Sciences.

[41]  K. Chaudhuri,et al.  Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease , 2013 .

[42]  Y. Agid,et al.  Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior , 2007, Proceedings of the National Academy of Sciences.

[43]  P. A. House,et al.  Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .

[44]  S. Fox,et al.  Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease , 2013, Neurotherapeutics.

[45]  Matteo Pizzorno,et al.  Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. , 2007, Parkinsonism & related disorders.

[46]  A. Jackson,et al.  Psychological therapies for pathological and problem gambling. , 2012, The Cochrane database of systematic reviews.

[47]  A. Lang,et al.  Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study , 2010, Annals of neurology.

[48]  D. Riley Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. , 2002, Clinical neuropharmacology.

[49]  A. Lang,et al.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.

[50]  V. Shanker,et al.  Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. , 2015, Neurology.

[51]  B. Bloem,et al.  Letters to the Editor Related to New Topics Reversible Parkinsonism After Chronic Cyclosporin Treatment in Renal Transplantation , 2009 .

[52]  A. Strafella,et al.  Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[53]  A. Lawrence,et al.  Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease , 2009, Journal of Clinical Neuroscience.

[54]  W. Fratta,et al.  Differential effect of opioid and cannabinoid receptor blockade on heroin‐seeking reinstatement and cannabinoid substitution in heroin‐abstinent rats , 2011, British journal of pharmacology.

[55]  J. Friedman,et al.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.

[56]  M. Nirenberg,et al.  Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.

[57]  P. Svenningsson,et al.  EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[58]  M Tagliati,et al.  Subthalamic deep brain stimulation and impulse control in Parkinson’s disease , 2009, European journal of neurology.

[59]  Eric Seigneuret,et al.  Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. , 2012, Brain : a journal of neurology.

[60]  M. Mark,et al.  Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. , 2011, The American journal of psychiatry.

[61]  A. David,et al.  Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers , 2013, Neurology.

[62]  J. Régis,et al.  Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[63]  P. Keck,et al.  Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. , 2008, The Journal of clinical psychiatry.

[64]  J. Brotchie,et al.  α1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques , 2009, Journal of Pharmacology and Experimental Therapeutics.

[65]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[66]  J. Friedman,et al.  Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[67]  JaneR . Taylor,et al.  Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task , 2014, Behavioural Brain Research.

[68]  S. Owen,et al.  Stroke services, stroke networks: is there an ideal model? , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[69]  C. Honey,et al.  Hypomania as an adverse effect of subthalamic nucleus stimulation: report of two cases , 2006, Acta Neurochirurgica.

[70]  Trevor W Robbins,et al.  The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats , 2008, Nature Protocols.

[71]  H. Steiger,et al.  Cognitive-Behavioral Therapy for Pathological Gambling in Parkinson’s Disease: A Pilot Controlled Study , 2012, European Addiction Research.

[72]  M. Onofrj,et al.  Pathological gambling in Parkinson disease is reduced by amantadine , 2010, Annals of neurology.

[73]  J. Brotchie,et al.  Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.

[74]  David Garcia-Garcia,et al.  Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. , 2011, Brain : a journal of neurology.

[75]  Antonio Daniele,et al.  Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[76]  M. Nirenberg Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care , 2013, Drugs & Aging.

[77]  A. David,et al.  Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. , 2012, Parkinsonism & Related Disorders.

[78]  G. Deuschl,et al.  Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.

[79]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[80]  E. López‐Valdés,et al.  Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[81]  Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. , 2013, Parkinsonism & related disorders.

[82]  S. Houle,et al.  Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.

[83]  Michael S. Okun,et al.  Effects of STN and GPi Deep Brain Stimulation on Impulse Control Disorders and Dopamine Dysregulation Syndrome , 2012, PloS one.

[84]  A. Antonini Continuous dopaminergic stimulation--from theory to clinical practice. , 2007, Parkinsonism & related disorders.

[85]  J. Régis,et al.  Addiction in Parkinson's disease: Impact of subthalamic nucleus deep brain stimulation , 2005, Movement disorders : official journal of the Movement Disorder Society.

[86]  Y. Agid,et al.  Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation , 2006, Movement disorders : official journal of the Movement Disorder Society.

[87]  A. David,et al.  Managing impulse control behaviours in Parkinson's disease: practical guidelines. , 2013, British journal of hospital medicine.

[88]  E. Foncke,et al.  Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[89]  Valerie Voon,et al.  Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[90]  J. Schneider,et al.  The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. , 2010, The international journal of neuropsychopharmacology.

[91]  J. Friedman,et al.  Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. , 1995, The Journal of clinical psychiatry.

[92]  J. Brotchie,et al.  L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.

[93]  Marios Politis,et al.  Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. , 2011, Brain : a journal of neurology.

[94]  M. Hallett,et al.  Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors , 2010, Neuron.